Cross Nagasaki Genbaku Hospital. Patients received RAM 8 mg/kg intravenously on days 1 and 15, plus PTX 80 mg/m2 intravenously on days 1, 8, and 15 of a 28-day cycle. The overall response rate (RR) by Response Evaluation Criteria in Solid Tumors guidelines version 1.1 and progression-free survival (PFS) were evaluated. In addition, the same analysis was conducted for S-1 refractory relapse gastric cancer at our hospital. Results: Fourteen patients received RAM plus PTX. The RR for 8 assessable patients was 37.5% (95% Confidence Interval (CI), 8.5-75.5), the median PFS was 5.2 months, and the RR for 4 assessable patients was 50% (95% CI,.2), the median PFS was 5.0 months in S-1 refractory relapse gastric cancer patients who received RAM plus PTX as 2nd line.
Background: In Indonesia, breast cancer has the 2nd highest prevalence among cancer diseases. Earlier research findings showed that the first chemotherapy decrease patient's quality of life, but others gave different results. The aim of this study is to know the effects of first chemotherapy on breast cancer patient's quality of life. Methods: This study is a prospective cohort study from December 2016 until January 2017. The quality of life of early stage breast cancer patients who had recently received chemotherapy in Siloam General Hospital were evaluated using EORTC QLQ-C30 questionnaire. Patients receiving hormonal therapy, having comorbid disease, or diagnosed with stage IV breast cancer were excluded. Statistical analysis was done using Wilcoxon Test. Results: A total of 30 patients, with median age were included to the study. All patients did not smoke nor consume alcohol. From 30 patients, 23.33% had relatives diagnosed with cancer. The majority of patients were Sundanese ethnic (50%) and Islamic (93.33%). Furthermore, 36% were elementary school graduate and 33.33% were junior high school graduate. In addition, 70% of patients had monthly income above minimum regional wage. Most patients (76.66%) received FEC chemotherapy regimen and 13.33% received CyclophosphamideDoxorubicin regimen. From EORTC-QLQ C30 questionnaire, the first chemotherapy on early stage breast cancer patients significantly decrease patient's quality of life in role functioning (p ¼ 0.047), social functioning (p ¼ 0.031), and financial difficulties (p ¼ 0.016), nausea-vomiting (p ¼ 0.041) and appetite loss (p ¼ 0.002). There were no significant changes on other aspects of quality of life.
Conclusion:
The first chemotherapy significantly decreased patient's quality of life in role functioning, social functioning, financial difficulties, nausea-vomiting, and appetite loss. Background: Recent data have reported that tumor infiltrating lymphocytes (TILs) can be a predictive factor in Trastuzumab-treated HER2-positive breast cancer. However, whether TILs are also predictive in Pertuzumab-treated breast cancer remains unknown. Methods: We evaluated stromal TILs in biopsy samples of 17 HER2-positive breast cancer patients who received neoadjuvant chemotherapy with anthracycline followed by paclitaxel plus Trastuzumab (wPTXþT) or docetaxel plus Pertuzumab and Trastuzumab (PTD). We retrospectively investigated the relationship between the response to neoadjuvant chemotherapy and TILs. Results: Median age was 56 years (range: 29-72). A total of 17 patients were comprising 8 stage II (32%) and 9 stage III (68%), 8 ER-positive (47%) and 9 ER-negative (53%). 10 patients (59%) received wPTXþT and 7 (41%) received PTD therapy. The frequencies of TILs were as follows; <5%TILs, 5-50%TILs and > 50%TILs were 9 (53%), 6 (35%) and 2 (12%) patients, respectively. pCR rate of all patients was 41%(7/17), with frequencies of 67%, 13% in ER-negative, positive, respectively. 63% (5/8) of tumors with high TILs (>5%TILs) achieved pCR. In addition, 2 ER-negative tumors with low TILs (<5%TILs) also achieved pCR. From the viewpoint of regimens, 50% (5/10) of patients achieved pCR in wPTXþT treated group and 28%(2/7) in PTD treated group. pCR patients in wPTXþT treated group were all ER-negative. In contrast, a patient with ER-positive and high TILs (>5%) Background: Secondary therapy of the progressive stomach cancer increased ramucirumab (as follows: RAM) in Japan in 2015, and a choice spread while there were many patients who could not be cured by the first in treatment, and reached the secondary therapy with progressive stomach cancer. Because we detected a return current disorder due to lymphatic obstruction in the patients using RAMþPTX this time, we report it here. case: An 80 years old man. In 2015.3 this hospital after gastric cancer full extraction. There is the metastasis to lymph nodes, too, and it seems to be high-risk, and it is started DOCþTS-1 by 2015.4. A taking 2015.5 TS-1 mistake is found out. It is talked by a chief physician, and we take the family out of the hospital drugstore and adjustment, but we judge that it has difficulty with TS-1 continuation, and suggestion starts Weekly-PTX in anticipation of RAM addition. 2015.7 RAMþPTX initiation. A blood count level, urinalysis level normal. ALP at the time of 46.4 kg in weight day15 of 2015.10 RAM-PTX 4 course eyes day1 time: 410. 2015.12 weight 47.6kgALP: 395. Because diarrhea continues from the end of November, only RAM alone takes effect on December 22. Impression-related edema is detected from the 2016.1.5 both sides thigh to the tip. RAMþPTX cancellation. It is significant 2016.1.15 pleural effusion, ascites. Return current disorder suspicion due to obstruction lymphatic without the indication of the neoplastic lesion. On January 20, it is 62.5 kg in weight. 2.17 urinary retention. The Silodosin continuation. Tadalafil addition. 2016.4.13 pleural effusion, the ascitic fluid are tendencies to decrease, too. Edema of the 2016.5.11 culf is mild. There is no most of the ascitic fluid. 2016.6.8 edema almost disappears. 47 kg in weight. Conclusion: The pharmacist of this hospital shares patients information as a team, too and intervenes comprehensively and positively. It seems to be a very rare case and reports this case. 
